A role of oxidative stress-generated eicosanoid in the progression of arteriosclerosis in type 2 diabetes mellitus model rats

Hypertension Research

Volumn 25, Issue 1, 2002, Pages 91-98

  Shinomiya, Kaori ^a   Fukunaga, Megumu ^a   Kiyomoto, Hideyasu ^a   Mizushige, Katsufumi ^a   Tsuji, Teppei ^a   Noma, Takahisa ^a   Ohmori, Koji ^a   Kohno, Masakazu ^a   Senda, Senda ^a  

^a KAGAWA UNIVERSITY   (Japan)

Author keywords

Arteriosclerosis; Diabetes mellitus; Insulin resistance; Isoprostanes; Oxidative stress

Indexed keywords

8 ISOPROSTAGLANDIN E2; ALPHA TOCOPHEROL; ALPHA TOCOPHEROL DERIVATIVE; ANTIOXIDANT; ICOSANOID; INSULIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1; TROGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; AORTA MEDIA; ARTICLE; CARDIOVASCULAR DISEASE; CELL COUNT; CELL NUCLEUS; CONTROLLED STUDY; DISEASE COURSE; ELECTROIMMUNOASSAY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INSULIN RESISTANCE; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; RISK FACTOR; SMOOTH MUSCLE FIBER;

ANIMALS; AORTA; ARTERIOSCLEROSIS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DINOPROST; DISEASE PROGRESSION; EICOSANOIDS; F2-ISOPROSTANES; LIPIDS; MALE; OXIDATIVE STRESS; RATS; RATS, INBRED OLETF; RATS, LONG-EVANS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 0036191310     PISSN: 09169636     EISSN: None     Source Type: Journal    
DOI: 10.1291/hypres.25.91     Document Type: Article

References (39)

1. Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial: Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes
2. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): Effects on mortality at 1 year
3. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
4. Blood pressure control in Japanese hypertensives with or without type 2 diabetes mellitus
5. Advanced protein glycosylation in diabetes and aging
6. Recent progress in advanced glycation end products and diabetic complications
7. Role of oxidative stress in development of complications in diabetes
8. Oxidative stress and diabetic vascular complications
9. The role of oxidative stress in neuropathy and other diabetic complications
10. Changing concepts of atherogenesis
11. Cross talk between angiotensin II type 1 and type 2 receptors; cellular mechanism of angiotensin type 2 receptor-mediated cell growth inhibition
12. Tyrosine-kinase dependent TGF-β and extracellular matrix expression by mechanical stretch in vascular smooth muscle cells
13. Diabetic microvascular complications and growth factors
14. Role of transforming growth factor beta in human disease
15. TGF-betas and TGF-beta receptors in atherosclerosis
16. New roles of low density lipoproteins and vitamin E in the pathogenesis of atherosclerosis
17. The generation and actions of Isoprostanes
18. 2-like compounds are produced in vivo in humans by a non-cyclooxigenase free radical-catalyzed mechanism
19. Formation of noncyclooxygenase-derived prostanoids (F2-isoprostanes) in plasma and low density lipoprotein exposed to oxidative stress in vitro
20. α, in the rat: Evidence for interaction with thromboxane A2 receptors
21. Evidence for the existence of F2-isoprostane receptors on rat vascular smooth muscle cells
22. α is not mediated by thromboxane receptor isoforms
23. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers: Smoking as a cause of oxidative damage
24. Modulation of oxidant stress in vivo in chronic cigarette smokers
25. 2 alpha generation during coronary reperfusion: A potential quantitative marker of oxidant stress in vivo
26. 2alpha in acute coronary angioplasty: Evidence for oxidant stress during coronary reperfusion in humans
27. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge heart antioxidant study (CHAOS)
28. Antioxidant vitamins and cardiovascular disease
29. Characteristic of diabetes, blood pressure, and cardiac and renal complications in Otsuka Long-Evans Tokushima Fatty rats
30. 2-isoprostanes in biological fluids and tissues as a measure of oxidant stress
31. Effects of troglitazone on collagen accumulation and distensibility of aortic wall in prestage of non-insulin dependent diabetes mellitus of Otsuka Long-Evans Tokushima Fatty rats
32. Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of a Type II diabetic rat model
33. Beneficial effects of antioxidants in diabetes: Possible protection of pancreatic β-cells against glucose toxicity
34. Differential responsiveness to insulin of endothelial support cells from micro- and macrovessels
35. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia
36. Active oxygen species stimulate vascular smooth muscle cell growth and proto-oncogene expression
37. Antioxidants inhibit JNK and p38 MAPK activation but not ERK 1/2 activation by angiotensin II in rat aortic smooth muscle cells
38. 2-isoprostanes mediate high glucose-induced TGF-β synthesis and glomerular proteinuria in experimental type I diabetes
39. 2 -isoprostane in vascular smooth muscle cells by elevated glucose and growth factors